Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

U of M researchers identify genetic variation behind acute myeloid leukemia treatment success

27.02.2013
Researchers from the College of Pharmacy and Medical School working within the Masonic Cancer Center, University of Minnesota, have partnered to identify genetic variations that may help signal which acute myeloid leukemia (AML) patients will benefit or not benefit from one of the newest antileukemic agents.

Their study is published today in Clinical Cancer Research.

In the latest study, U of M researchers evaluated how inherited genetic polymorphisms in CD33, a protein that naturally occurs in most leukemia cells, could affect clinical outcomes of patients treated with an existing chemotherapy drug, gemtuzumab ozogamicin (GO), an immuno-conjugate between anti-CD33 antibody and a cytotoxin known as calicheamicin, which binds to CD33 on leukemic cells. As GO is internalized by leukemia cells, the cytotoxin is released, causing DNA damage and generating leukemic cell death.

In recent clinical trials GO has been shown to induce remission and improve survival in subset of patients with AML, however there is wide inter-patient variation in response.

Jatinder Lamba, Ph.D., and colleagues identified and evaluated three genetic variations of CD33 in two groups of patients with pediatric AML – one group that received the drug GO, and one group that did not. They found that specific genetic variation in CD33 that significantly affected the clinical outcome of AML patients who received GO based chemotherapy.

"Understanding how genetics play a role in how drugs work is extremely useful, particularly for a drug like GO which has shown a very heterogeneous response in AML patients," said Jatinder Lamba, Ph.D., the study's lead author and a researcher who holds appointments in both the College of Pharmacy and the Masonic Cancer Center, University of Minnesota. "Our latest findings lead us to believe that genetic variation in CD33 influences how AML patients' leukemic cell responds to GO."

AML is a cancer of the blood and bone marrow, and is the second most common form of leukemia in children. Though the most common type of treatment for AML is chemotherapy, Lamba says the disease remains hard to treat and newer, more effective therapies are needed.

"The overall goal of our study was to use genetic data to predict beneficial or adverse response to a specific drug, thus opening up opportunities to use this information for drug optimization to achieve maximum therapeutic efficacy and minimum toxicity. Our hope is that our research could serve as a marker of prognostic significance for clinicians to select the therapy that has the greatest odds of being effective for individual patients based on their CD33 genotype."

Other University of Minnesota researchers involved in the study include Leslie Mortland, M.D., from the University of Minnesota Medical School and Betsy Hirsch, Ph.D., from the Medical School and the Masonic Cancer Center, University of Minnesota.

The University of Minnesota College of Pharmacy, the only school of pharmacy in Minnesota, offers its program on the Twin Cities and Duluth campuses. Founded in 1892, the College of Pharmacy educates pharmacists and scientists and engages in research and practice to improve the health of the people of Minnesota and society. The college is part of the Academic Health Center, which is home to the University of Minnesota's six health professional schools and colleges as well as several health-related centers and institutes. Learn more at www.pharmacy.umn.edu.

The University of Minnesota Medical School, with its two campuses in the Twin Cities and Duluth, is a leading educator of the next generation of physicians. Our graduates and the school's 3,800 faculty physicians and scientists advance patient care, discover biomedical research breakthroughs with more than $180 million in sponsored research annually, and enhance health through world-class patient care for the state of Minnesota and beyond. Visit www.med.umn.edu to learn more.

Masonic Cancer Center, University of Minnesota is part of the University's Academic Health Center. It is designated by the National Cancer Institute as a Comprehensive Cancer Center. For more information about the Masonic Cancer Center, visit www.cancer.umn.edu or call 612-624-2620.

Amy Leslie | EurekAlert!
Further information:
http://www.umn.edu

More articles from Life Sciences:

nachricht New Technique Maps Elusive Chemical Markers on Proteins
03.07.2015 | Salk Institute for Biological Studies

nachricht New approach to targeted cancer therapy
03.07.2015 | CECAD - Cluster of Excellence at the University of Cologne

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Forschungsschiff Heincke seit 25 Jahren im Dienst der Wissenschaft

Ein Vierteljahrhundert alt, über 900.000 Kilometer (488.842 nautische Meilen) gefahren und trotzdem auf dem neuesten wissenschaftlichen und technischen Stand: Die Indienststellung des Forschungsschiffes Heincke jährt sich am 8. Juli 2015 zum 25. Mal.

Wissenschaftler des Alfred-Wegener-Instituts, Helmholtz-Zentrum für Polar- und Meeresforschung (AWI), das die Heincke betreibt, nehmen ebenso regelmäßig an...

Im Focus: Solardächer produzieren Strom für Fahrzeuge

Studentische Industriekooperation zwischen HAW Hamburg und Webasto erarbeitet Ergebnisse für EU-Zertifizierungsprozess von Solardächern zur Verbesserung der Öko-Bilanz von Fahrzeugen.

Unter der Leitung von Dr.-Ing. Volker Skwarek, Professor für technische Informatik an der HAW Hamburg, erarbeiteten sechs Studierende des...

Im Focus: Viaducts with wind turbines, the new renewable energy source

Wind turbines could be installed under some of the biggest bridges on the road network to produce electricity. So it is confirmed by calculations carried out by a European researchers team, that have taken a viaduct in the Canary Islands as a reference. This concept could be applied in heavily built-up territories or natural areas with new constructions limitations.

The Juncal Viaduct, in Gran Canaria, has served as a reference for Spanish and British researchers to verify that the wind blowing between the pillars on this...

Im Focus: Aus alt mach neu - Rohstoffquelle Elektroschrott

Der Markt für Unterhaltungselektronik boomt: Rund 60 Millionen Fernsehgeräte wurden im letzten Jahr in Europa verkauft. Früher oder später werden sie zurückkehren – als Elektroschrott.

Die Recycling-Industrie hat darauf reagiert: Kupfer, Aluminium, Eisen- und Edelmetalle sowie ausgewählte Kunststoffe werden bereits wiederverwertet. Allerdings...

Im Focus: Radar schützt vor Weltraummüll

Die Bedrohung im All durch Weltraummüll ist groß. Aktive Satelliten und Raumfahrzeuge können beschädigt oder zerstört werden. Ein neues, nationales Weltraumüberwachungssystem soll ab 2018 vor Gefahren im Orbit schützen. Fraunhofer-Forscher entwickeln das Radar im Auftrag des DLR Raumfahrtmanagement.

Die »Verkehrssituation« im All ist angespannt: Neben unzähligen Satelliten umkreisen Weltraumtrümmer wie beispielsweise ausgebrannte Raketenstufen und...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Flurförderzeuge im Zeichen der Zeit

03.07.2015 | Veranstaltungen

Aktuelles aus Forschung und Betrieb: 27. Deutscher Flammentag

02.07.2015 | Veranstaltungen

Call for ideas: Gute Ideen für bessere Städte

02.07.2015 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Siemens erhält Auftrag für Offshore-Windkraftwerk in Großbritannien

03.07.2015 | Unternehmensmeldung

Flurförderzeuge im Zeichen der Zeit

03.07.2015 | Veranstaltungsnachrichten

Kompakter Time Converter für zuverlässigen Einsatz in rauen Umgebungen

03.07.2015 | Energie und Elektrotechnik